Illustrative image.
Elrexfio
Elranatamab‑bcmm
$27860.00
44ml · 4 × 1 vial · 1 month supply
BrandBranded medicine· By Pfizer
$27860.00 per month
Strength
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$362180a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
44ml
76ML
FDA boxed warningCytokine release syndrome and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome
Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity.
Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions, can occur in patients receiving ELREXFIO. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment. Withhold ELREXFIO until the neurologic toxicity resolves or permanently discontinue based on severity.
Because of the risk of CRS and neurologic toxicity, including ICANS, ELREXFIO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ELREXFIO REMS.
Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity.
ELREXFIO is available only through a restricted program called the ELREXFIO Risk Evaluation and Mitigation Strategy (REMS).
About Elrexfio
Overview
Elrexfio (elranatamab-bcmm) is an antibody medicine supplied in a vial for injection under the skin. It treats adults with multiple myeloma that has returned or has not responded to treatment after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. It works by linking T cells to myeloma cells carrying a protein called BCMA, activating the T cells to destroy those cells. Its FDA accelerated approval is based on response rates and how long responses lasted; continued approval may depend on trials confirming clinical benefit.
What it treats
• Multiple myeloma in adults whose disease has returned or has not responded to treatment after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Safety information
Side effects
Common side effects include cytokine release syndrome (CRS), tiredness, injection-site reactions, diarrhea, upper respiratory tract infections, muscle and bone pain, pneumonia, decreased appetite, rash, cough, nausea and fever. Serious side effects that warrant contacting a doctor include CRS, nervous system toxicity including immune effector cell-associated neurotoxicity syndrome (ICANS), and infections that can be severe, life-threatening or fatal. Pneumonia and other infections listed among common side effects can also be serious. Severe reductions in lymphocytes, neutrophils and other white blood cells, hemoglobin, and platelets can occur. Liver toxicity, including increased liver enzymes and bilirubin, can also occur. Blood counts and liver tests are monitored before and during treatment. Treatment should not begin if you have an active infection. Elrexfio may harm an unborn baby. If you can become pregnant, use effective contraception.
FDA boxed warning
Cytokine release syndrome and neurologic toxicity including immune effector cell-associated neurotoxicity syndrome
Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity.
Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions, can occur in patients receiving ELREXFIO. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment. Withhold ELREXFIO until the neurologic toxicity resolves or permanently discontinue based on severity.
Because of the risk of CRS and neurologic toxicity, including ICANS, ELREXFIO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ELREXFIO REMS.
Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity.
ELREXFIO is available only through a restricted program called the ELREXFIO Risk Evaluation and Mitigation Strategy (REMS).
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The label lists no formal contraindications for Elrexfio. However, treatment should not begin in anyone with an active infection. Elrexfio can cause severe, life-threatening or fatal infections; patients should be monitored for signs and symptoms and treated appropriately. Other precautions include: - Low neutrophil counts (neutropenia): complete blood cell counts should be checked before and periodically during treatment. - Liver toxicity: liver enzymes and bilirubin should be checked before treatment and during treatment as clinically indicated. - Pregnancy: Elrexfio may harm an unborn baby. Women who could become pregnant should use effective contraception. - Breastfeeding: patients should not breastfeed during treatment.
Interactions
Elrexfio can slow the activity of liver enzymes called CYP enzymes, which break down certain medicines. This may increase the levels of those medicines in the body. For some medicines, even small increases can cause serious side effects. This risk is more likely early in treatment and during and after cytokine release syndrome (CRS). Review your other medicines with your doctor, who may need to monitor their levels or check for signs of toxicity.
Using Elrexfio
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label ELREXFIO (ELRANATAMAB-BCMM) INJECTION, SOLUTION [PFIZER LABORATORIES DIV PFIZER INC] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00